Beijing Mabworks Scores World-First Phase III Win In Membranous Nephropathy

 
• By Dexter Jie Yan
  
Patients with primary membranous nephropathy (pMN) have yet to have a therapy apporved on the basis of late-stage trial outcomes. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D